Table 4 |
||||
|
Risk of mortality and cardiovascular disease associated with gout |
||||
|
Study estimate (95% CI) |
Design |
Population |
Comparison |
Multivariate risk |
|
|
||||
|
All-cause mortality |
||||
|
HPFS [73] |
Cohort: stratified by baseline CHD status |
51,927 male health professionals, 40 to 75 years old |
CHD: gout vs. no gout |
RR = 1.25 (1.09, 1.45) |
|
No CHD: gout vs. no gout |
RR = 1.28 (1.15, 1.41) |
|||
|
MRFIT [74] |
MRFIT RCT participants |
9,105 men, 41 to 63 years old |
Gout vs. no gout |
HR = 1.09 (1.00, 1.19) |
|
CGMH [75] |
Cohort: health screening programme participants |
61,527 men and women, 30 to 74 years old |
Gout vs. normouricaemia |
HR = 1.46 (1.12, 1.91) |
|
All cardiovascular death |
||||
|
HPFS [73] |
Cohort: stratified by baseline CHD status |
51,927 male health professionals, 40 to 75 years old |
CHD: gout vs. no gout |
RR = 1.26 (1.07, 1.50) |
|
No CHD: gout vs. no gout |
RR = 1.38 (1.15, 1.66) |
|||
|
MRFIT [74] |
MRFIT RCT participants |
9,105 men, 41 to 63 years old |
Gout vs. no gout |
HR = 1.21 (0.99, 1.49) |
|
CGMH [75] |
Cohort: health screening programme participants |
61,527 men and women, 30 to 74 years old |
Gout vs. normouricaemia |
HR = 1.97 (1.08, 3.59) |
|
Fatal CHD |
||||
|
HPFS [73] |
Cohort: stratified by baseline CHD status |
51,927 male health professionals, 40 to 75 years old |
CHD: gout vs. no gout |
RR = 1.24 (1.04, 1.49) |
|
No CHD: gout vs. no gout |
RR = 1.55 (1.24, 1.93) |
|||
|
MRFIT [74] |
MRFIT RCT participants |
9,105 men, 41 to 63 years old |
Gout vs. no gout |
HR = 1.35 (1.06, 1.72) |
|
Fatal myocardial infarction |
||||
|
MRFIT [74] |
MRFIT RCT participants |
9,105 men, 41 to 63 years old |
Gout vs. no gout |
HR = 1.35 (0.94, 1.93) |
|
Cardiovascular disease |
||||
|
Dutch primary care [76] |
Follow-up of case-control study participants |
261 men and women |
Gout vs. no gout |
RR = 0.98 (0.65, 1.47) |
|
Coronary heart disease |
||||
|
Framingham Study [78] |
Cohort |
2,316 men |
Gout vs. no gout |
RR = 1.6 (1.1, 2.5) |
|
Meharry-Hopkins Study [77] |
Cohort |
1,552 male physicians |
Gout vs. no gout |
RR = 0.59 (0.24, 1.46) |
|
GPRD [13] |
Case-control |
207,350 men and women |
Gout vs. osteoarthritis |
OR = 1.75 (1.70, 1.79) |
|
Myocardial infarction |
||||
|
Framingham Study [78] |
Cohort |
2,316 men |
Gout vs. no gout |
RR = 1.5 (0.9, 2.6) |
|
MRFIT [79] |
MRFIT RCT participants |
12,866 men |
Gout vs. no gout |
OR = 1.26 (1.14, 1.40) |
|
Angina pectoris |
||||
|
Framingham Study [78] |
Cohort |
2,316 men |
Gout vs. no gout |
RR = 1.8 (1.1, 3.2) |
|
|
||||
|
CGMH, Chang Gung Memorial Hospital; CHD, coronary heart disease; CI, confidence interval; GPRD, General Practice Research Database; HPFS, Health Professionals Follow-up Study; HR, hazard ratio; MRFIT, Multiple Risk Factor Intervention Trial; OR, odds ratio; RCT, randomised controlled trial; RR, relative risk. |
||||
|
Roddy and Doherty Arthritis Research & Therapy 2010 12:223 doi:10.1186/ar3199 |
||||